The Essence of Zartaux

Our heritage in Swiss Precision

Zartaux traces its roots to Switzerland, where it set out to merge Swiss precision with forward-thinking research, transforming beauty with patented technologies that fuse high-concentration actives into enriched, unparalleled anti-aging skincare solutions. This starting point established a culture of meticulous quality and evidence-driven development that still defines the company today.

Early Biotechnology Focus

In a small laboratory, the brand's founders redirected R&D toward high-performance skincare actives. They collaborated with biotech startups to explore recombinant peptides, growth factors, and novel encapsulation techniques long before such terms became industry buzzwords. Pilot batches consistently outperformed conventional cosmetics in both safety and efficacy tests, convincing them that biotechnology would define the future of aesthetic medicine.

Zartaux Brand Formal Establishment

Recognizing the need for a dedicated commercial entity, the brand's founders embraced early biotechnology and incorporated these innovations into new formulations, preparing the ground for future patented technologies. Zartaux Brand was officially launched with the debut of its GMP-certified first release of professional skincare treatments for practitioners. These groundbreaking products paved the way for international expansion and signaled the brand's commitment and dedication to premium standards in skin rejuvenation, enhancing global trust in the brand's skincare excellence through pioneering multi-active formulations.

ISO Quality Achieved

The company secured dual ISO Certifications for quality management and SkinNovelties production. Achieving these standards at this early stage allowed us to institute a closed-loop feedback system of clinical researchers, manufacturing engineers, and quality auditors collaborating to refine every variable, based on real-world data supplied by our independent physician advisory board, ensuring that every formulation would be backed by clinical evidence before entering the market.

Birth of S.C.E.D.I.S.™ Technology

After four years of iterative prototyping, Zartaux initiated extensive testing of its Aesthetic Medical SkinNovelties, collaborating with independent expert practitioners to document statistically significant improvements in hydration, elasticity, and collagen density. The brand introduced the proprietary S.C.E.D.I.S.™ Technology, optimizing microstructure to release hyaluronic acid, peptides, and vitamins at clinically meaningful concentrations nearly double the market norm at the time. The evidence base built in that year has now grown to robust clinical data supporting the technology.

Portfolio Expansion & Global Presence

With S.C.E.D.I.S.™ established, the brand broadened its scope to underserved indications such as, Periocular sensitivity through ultra-light formulations to combat dark circles and puffiness without edema, Dynamic wrinkle modulation with peptide boosters designed to extend the interval between botulinum toxin sessions and Scalp revitalization using liposomal growth factors combined with stem-cell conditioned media to address androgenic alopecia. Patents were presented at IMCAS, AMWC, Dubai Derma, and EADV congress circuits, offering masterclasses that helped thousands of clinicians integrate evidence-based skin therapeutics into their practices. 

Enhanced R&D under SwissPharma Dynamic

Operating through SwissPharma Dynamic, Zartaux intensified research into dermal fillers and regenerative therapies, secured additional patents, completed supporting trials, and introduced multi-peptide and multi-vitamin anti-aging solutions, all aimed at greater product durability and consumer satisfaction. The company intensified exploratory work on covering a tri-peptide self-assembly technology and an amino-acid–stabilized HA cross-linker. By year-end, pilot trials demonstrated visible lifting effects within 48 hours and durability beyond 12 months, pushing patient-satisfaction scores to 96%.

Growth with Stem Cells & New Product Segments

A strategic alliance with a Japanese cell institute enabled us to incorporate plant-derived stem cells, resulting in boosted fibroblast activity by 42% in vitro. A strong marketing push and the integration of unique stem cell-based ingredients fueled marked sales growth. Zartaux obtained an EU Medical Devices License, opened distribution in 28 EU states, and pursued further national approvals for injectable fillers. Product extensions into cellulite care, sun protection, and regeneration products paved the way for holistic treatment protocols, bolstering the company's global position.

Navigating a Global Crisis, Cementing Leadership

Despite global challenges, demand for Zartaux's patented injectable medical devices surged. Its CE-certified dermal fillers, backed by Z.A.E.M.A Academy training, highlighted resilience and leadership. The pandemic disrupted elective procedures, prompting the Academy's shift to virtual training on product handling and injection anatomy. We redirected logistics to maintain cold-chain integrity during flight shortages, ensuring supply globally. Surveys showed a 92% retention rate among clinics that had adopted our fillers pre-2020.

Evidence-Based Outreach and Publications

Collaborations with leading European hospitals and global events like EADV and ISAPS advanced Zartaux's patented S.C.E.D.I.S.™ (UK00003391734) technology. In partnership with the Z.A.E.M.A Academy, the company published scientific papers on the long-term efficacy and safety of its hyaluronic-acid fillers. Collaborations with universities and hospitals culminated in a landmark series in scientific journals, documenting 24-month follow-up data and sustained natural texture integration. Presentations at EADV, ISAPS, and regional societies translated these findings into updated treatment algorithms, positioning Zartaux as a reference brand for evidence-driven aesthetic medicine

Strategic Acquisition & Swiss Reintegration

The acquisition of Swiss Pharma, rebranded as Sandine Zartaux Switzerland AG, bolstered the brand's innovation pipeline in Switzerland. Strategic partnerships were forged, introducing patented next-generation biostimulators known as Exostems, which blend plant stem cells with PDRN, also known as salmon sperm, as well as the iStem Range Skincare, consisting of a regenerative compound that promotes tissue repair, stimulates collagen production, and enhances cell turnover for improved skin healing and rejuvenation. Through Sandine Zartaux Holding, the brand continues broadening its offerings by harnessing distinctive ingredients and partnerships to address varied needs in aesthetic medicine. Explore our latest innovations.

Looking Ahead

Grounded in almost six decades, global clinical partnerships, and relentless scientific curiosity, Sandine Zartaux remains devoted to one objective: delivering aesthetic solutions that are as safe and sophisticated as the patients and professionals who trust them. Each breakthrough is a step toward a more precise, personalized, and sustainable future for skin health and rejuvenation. For us “Age is just a number”. This is not just a promise, it is the law of Zartaux!